How has Boston Scientific's uncapped contingent considertation changed year-over-year?

Boston Scientific's uncapped contingent considertation decreased by 12.6% year-over-year, from $151M to $132M.

Boston Scientific BSX Uncapped Contingent Considertation

Revenue$5.2B+11.6%

Gross profit$3.6B+12.6%

Operating income$1.1B+19.5%

Net income$1.3B+99.3%

EPS (diluted)$0.90+100%

Cash & equivalents$850.0M+146%

Total equity$25.9B+16.4%

Total assets$44.4B+10.5%

Operating cash flow$348.0M-35.7%

CapEx$177.0M-5.4%

Free cash flow$171.0M-51.7%

Market cap$67.32B-37.5%

P/E18.9×-34.3×

P/S3.3×-2.9×

Gross margin69.2%+0.5pp

Operating margin18.4%+2.2pp

Net margin17.3%+5.7pp

Return on equity14.8%+5.2pp

Debt / equity0×-0.5×

Current ratio1.9×+0.4×

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:UncappedContingentConsidertation.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Boston Scientific's uncapped contingent considertation?: Boston Scientific (BSX) reported uncapped contingent considertation of $132M in Q1 2026.
How has Boston Scientific's uncapped contingent considertation changed year-over-year?: Boston Scientific's uncapped contingent considertation decreased by 12.6% year-over-year, from $151M to $132M.